Table 2.
Efficacy of bevacizumab in the neoadjuvant and conversion treatment of patients with mCRC
| Study/name | N | Regimen | Response | PFS | S | Conversion to resectability/R0 hepatic resections |
|---|---|---|---|---|---|---|
| Retrospective studies | ||||||
| Terrebonne et al. [41] | 411 | Chemotherapy plus bevacizumab | Operated pts, 19 %: | Operated pts: | Operated patients: | Conversion to resectability: 19 % R0-R1: 86% |
| ETNA |
RR: 85 % CR: 33 % |
13.6 m |
1-year S rate: 94 % 2-year S rate: 82 % Median OS not reached |
|||
|
Non-operated pts, 81 %: RR: 49 % CR: 5 % |
Non-operated pts: 9.0 m |
Non-operated patients: 1-year S rate: 75 % 2-year S rate: 44 % Median OS: 21.9 m |
NR | |||
| Chaudhury et al. [42] | 35 | Oxaliplatin- and/or irinotecan-based chemotherapy plus bevacizumab | RR: 66 % | NR |
4-year S: 53 % Median OS: NR |
NR |
| Garcia et al. [43] | 20 | Chemotherapy plus bevacizumab | NR | NR | Median OS: 48.9 m | R0: 90 % |
| Ichante et al. [89] | 143 | FOLFIRI or XELIRI plus bevacizumab | NR |
10.0 vs. 9.0 m (with vs. without ETS) |
33.0 vs. 22.0 m (with vs. without ETS) | NR |
| Vera et al. [50] | 95 | Oxaliplatin- or irinotecan-based chemotherapy with or without bevacizumab |
RR: 51 % CR: 2 % Good pRR: 49 % vs. 27 % (with vs. without bevacizumab) |
NR | NR | NR |
| Prospective studies | ||||||
| Wong et al. [44] | 46 | XELOX plus bevacizumab | RR: 78 % |
6-m PFS: 73 % 12-m PFS: 50 % |
6-m S: 96 % 12-m S: 86 % |
Conversion to resectability: 40 % R0: 20 % |
| Gruenberger et al. [45] | 43 | XELOX plus bevacizumab | RR: 66 % | NR | NR | R0: 79 % |
| Masi et al. [46] | 57 | FOLFOXIRI plus bevacizumab |
RR: 77 % CR: 12 % |
10-m PFS: 74 % Median PFS: 13.1 m |
Median OS: 30.9 m | R0: 40 % |
| Okines et al. [17] NO16966 | 1400 | XELOX or FOLFOX with or without bevacizumab | NR | NR | 2-year OS: 91 % vs. 82 % (bevacizumab vs. placebo) | R0: 6 % vs. 5 % (bevacizumab vs. placebo) |
| Okines et al. [17] First BEAT | 1914 | Chemotherapy plus bevacizumab | NR | NR | Median OS: 21.4 m vs. not reached (no curative intent surgery vs. curative intent surgery | R0: 77 % |
| Gruenberger et al. [47] OLIVIA | 80 | mFOLFOX6 plus bevacizumab or FOLFOXIRI plus bevacizumab | RR: 62 % vs. 81 % | Median PFS: 11.5 vs. 18.6 m | Median OS: 32.2 m vs. not reached | R0: 23 % vs. 49 % |
CR complete response, ETS early tumor shrinkage, FOLFIRI irinotecan, 5-fluorouracil and leucovorin, FOLFOX oxaliplatin, 5-fluorouracil and leucovorin, FOLFOXIRI oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin, m months, mCRC metastatic colorectal cancer, NR not reported, pts patients, PFS progression-free survival, pRR pathological response rate, RR response rate, OS overall survival, S survival, XELIRI capecitabine and irinotecan, XELOX capecitabine and oxaliplatin